PAI-1 plays significant roles in cancer occurrence, relapse and multidrug resistance and is highly expressed in tumours. ACT001, which is currently in phase I clinical trials for the treatment of glioblastoma (GBM). However, the detailed molecular mechanism of ACT001 is still unclear. In this study, we investigated the effects of ACT001 on glioma cell proliferation and clarified its mechanism. We discovered that PAI-1 was the direct target of ACT001 by a cellular thermal shift assay. Then, the interaction between ACT001 and PAI-1 was verified by Biacore assays, thermal stability assays and ACT001 probe assays. Furthermore, from the proteomic analysis, we found that ACT001 directly binds PAI-1 to inhibit the PI3K/AKT pathway, which induces the inhibition of glioma cell proliferation, invasion and migration. Moreover, the combination of ACT001 and cisplatin showed a synergistic effect on the inhibition of glioma in vitro and in vivo. In conclusion, our findings demonstrate that PAI-1 is a new target of ACT001, the inhibition of PAI-1 induces glioma inhibition, and ACT001 has a synergistic effect with cisplatin through the inhibition of the PAI-1/PI3K/AKT pathway.
17 April 2019 in Journal of Translational Medicine
Glioma accounts for a large proportion of cancer, and an effective treatment for this disease is still lacking because of the absence of specific driver molecules. Current challenges in the treatment of glioma are the accurate and timely diagnosis of brain glioma and targeted treatment plans. To investigate the diagnostic biomarkers and prospective role of miRNAs in the tumorigenesis and progression of glioma, we analyzed the expression of miRNAs and key genes in glioma based on The Cancer Genome Atlas database. Of the 701 cases that were downloaded, five were normal and 696 were glioma. Then, 1626 differentially expressed genes were identified, and 173 aberrantly expressed miRNAs were calculated by edgeR. GO and KEGG pathway enrichment analyses were performed using Cytoscape software. A coexpression network was built by weighted correlation network analysis (WGCNA). A cell scratch test and transwell, cell apoptosis and cell cycle assays were performed to validate the function of hsa-let-7b-5p. Based on crosstalk genes in the KEGG, PPI network, and WGCNA analyses, PLK1, CCNA2, cyclin B2 (CCNB2), and AURKA were screened as candidate diagnostic marker genes. The survival analysis revealed that high mRNA expression of PLK1, CCNA2, and AURKA was significantly associated with poor overall survival. Furthermore, hsa-let-7b-5p was identified as a core miRNA in the regulation of candidate genes involved in glioma development. We confirmed that hsa-let-7b-5p could inhibit the migration, invasion, and cell cycle of glioma cells. This study provides four potential biomarkers for the diagnosis of glioma, offers a potential explanation of its pathogenesis, and proposes hsa-let-7b-5p as a therapeutic target.
A novel parameter of relative recovery (Rre) was defined and determined by online SPE-HPLC to characterize plasma protein binding (PPB) kinetics of highly plasma binding drugs. The proportional relationship of Rrewith koffof PPB has been established with a new SPE model. A rapid, easy to use method could potentially be used to categorize PK properties of the drug candidates in the decision process of drug discovery and development.
The olanzapine–fluoxetine augmentation strategy has been proved efficacious for treatment-resistant depression, psychotic depression and bipolar depression. To achieve efficient therapeutic drug monitoring (TDM), we develop an automated online SPE-LC-MS/MS method for the simultaneous quantification of olanzapine, fluoxetine and norfluoxetine in human plasma. After adding an internal standard of diphenhydramine and centrifugation, a 10 μL plasma sample was directly injected into the SPE cartridge. While the analytes were retained on the SPE cartridge, the endogenous materials were washed out by the loading solvent. Following the valve switching, the analytes were eluted from the SPE cartridge to the analytical column by gradient elution. The analytes were quantified using a triple-quadrupole tandem mass spectrometer. Calibration curves were linear over the concentration range of 0.25–50.00 ng mL−1 for olanzapine, and 0.50–100.00 ng mL−1 for fluoxetine and norfluoxetine. The intra- and inter-day precisions were within 1.17% and 4.63%. And the accuracies were between 95.60% and 101.48%. The mean matrix effect was in the range of 90.35% to 99.89% and mean recovery was in the range of 90.35% to 96.99%. This method has been successfully applied to two Chinese schizophrenia patients. The online SPE-LC-MS/MS method allows sensitive and robust quantification of olanzapine, fluoxetine and norfluoxetine for routine TDM in clinic.